Oxymetazoline

證據等級: L5

預測適應症: 3 個

Oxymetazoline: From Nasal Congestion (OTC Decongestant) to Nasal Cavity Disease

One-Sentence Summary

Oxymetazoline is a topical α1/α2-adrenergic agonist widely known as an over-the-counter nasal decongestant, though a formal original indication text is not available in the current evidence pack. The TxGNN model predicts it may be effective for Nasal Cavity Disease, with 18 clinical trials and 5 publications currently supporting this direction — several of which test oxymetazoline directly.

Quick Overview

Item	Content
Original Indication	Not formally recorded in this dataset; well-established clinical use is as a topical nasal decongestant (OTC)
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.96%
Evidence Level	L2
Market Status	Not Marketed
Number of Licenses	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (data gap DG002). Based on well-established pharmacological knowledge, oxymetazoline is a topical α1/α2-adrenergic receptor agonist that induces vasoconstriction of the nasal mucosal vasculature, reducing mucosal congestion and secretions. This is the same mechanism underlying its long-standing OTC use as a nasal decongestant.

The predicted new indication — “nasal cavity disease” — is mechanistically almost coextensive with this known pharmacological action: conditions involving nasal mucosal congestion, edema, and obstruction. Rather than representing a distant repurposing hypothesis, this prediction largely reaffirms the drug’s existing pharmacological class effect, which is directly supported by clinical trial evidence (e.g., a completed Phase 2 RCT on nasal congestion relief, and a trial directly testing 0.05% oxymetazoline against epinephrine before sinus surgery).

Because no formal original indication or licensed product record exists in this jurisdiction (market status: Not Marketed, 0 licenses), this candidate should be treated as a potential new market-entry/repurposing target requiring formal regulatory documentation, rather than a novel mechanistic hypothesis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03228914	Phase 4	Completed	20	Directly compares topical 0.05% oxymetazoline vs. 1:1000 epinephrine for blood loss and surgical field visualization prior to endoscopic sinus surgery
NCT00562120	Phase 2	Completed	21	Double-blind, double-dummy, placebo-controlled, 4-way crossover study using nasal allergen challenge and acoustic rhinometry to assess nasal congestion relief
NCT01411969	N/A	Completed	16	Acoustic rhinometry study using 0.05% oxymetazoline aerosol spray for nasal decongestion, evaluating rhinogram notches
NCT03380715	NA	Completed	106	Compares co-phenylcaine nasal spray (decongestant + local anesthetic) vs. nebulization prior to rigid nasoendoscopy
NCT03620513	Phase 4	Completed	160	Double-blind study evaluating topical anesthesia and/or decongestant pretreatment for comfort during fiberoptic nasal pharyngoscopy/laryngoscopy
NCT06443255	Phase 3	Completed	16	Blinded triple-crossover comparison of cocaine, lidocaine/xylometazoline (decongestant class), and saline for intranasal analgesia
NCT00147940	Phase 4	Terminated	20	Correlates nasal volume/cross-sectional area with nasalance scores via acoustic rhinometry and nasometry
NCT01974726	NA	Terminated	95	Evaluates Eustachian tube function tests in patients with middle-ear disease related to nasal/nasopharyngeal pathology
NCT03962634	Phase 2	Terminated	3	Compares Kovanaze (nasal mist anesthetic/decongestant combination) vs. articaine injection for dental pulpal anesthesia
NCT00015795	Phase 1	Completed	30	Investigates laryngeal airflow/resistance in abductor spasmodic dysphonia vs. healthy volunteers

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9929658	1998	Cohort	Annals of the New York Academy of Sciences	Assessed olfactory function changes and nasal volume (via acoustic rhinometry) during acute rhinitis
25496205	2015	Cohort	Journal of Plastic Surgery and Hand Surgery	Evaluated nasal patency by acoustic rhinometry in children with repaired cleft lip/palate vs. controls
8615587	1996	Animal (Preclinical)	Annals of Otology, Rhinology & Laryngology	Directly tested oxymetazoline nose drops’ effect on local tissue defense in experimental rabbit sinusitis
38024464	2023	Case report	Global Pediatric Health	Rare pediatric case of rhinoscleroma presenting with nasal obstruction
28490409	2017	Case series	American Journal of Rhinology & Allergy	Describes endoscopic coblation technique for nasal telangiectasias in hereditary hemorrhagic telangiectasia

US Market Information

Currently no marketing authorization or license records are available for this drug in this jurisdiction (market status: Not Marketed; 0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information. (Note: TFDA label warnings/contraindications are flagged as a blocking data gap — DG001 — and drug interaction data was queried but not found.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 2 RCT and a trial directly testing oxymetazoline itself in a decongestant role provide L2-level evidence, and the mechanistic rationale is strong since the predicted indication overlaps closely with the drug’s well-known pharmacological class effect. However, the absence of local market authorization, formal MOA documentation, and safety labeling data means the candidate cannot proceed without guardrails.

To proceed, the following is needed:

TFDA (or equivalent local regulator) label warnings and contraindications (blocking gap, DG001)
Formal mechanism of action documentation from DrugBank or equivalent source (DG002)
Confirmed original indication text and licensing status for this jurisdiction
Route/dosage-form compatibility assessment for the proposed new indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.